Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Positive outcome of Dynavax phase IIa asthma challenge study

Aug. 2, 2004

Antiinflammatory effects of PDE4 inhibitors on airways epithelial cell functions

July 21, 2004

NDA for Xopenex HFA MDI accepted for review

July 20, 2004

Boehringer Ingelheim discloses anticholinergic compounds

July 19, 2004

ZyComb shows efficacy and safety in phase III study

July 14, 2004

Pulmicort HFA-MDI completes phase III

July 13, 2004

Histamine H3 receptor modulators claimed by Kyowa Hakko

July 9, 2004

PDE4 inhibitors prepared and tested at elbion

July 8, 2004

Boehringer Ingelheim presents compounds for inflammatory and obstructive airways diseases

July 7, 2004

Novartis seeks European approval of Xolair for severe allergic asthma

July 7, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.